BackU.S. Stem Cell Overview

U.S. Stem Cell Long Term Debt

Latest long-term debt for USRM: $680K.

Get informed when a big investor buys or sells

+ Follow
Long Term Debt
$682044.00
↓ 5.54% YoYΔ $-40016.00 vs prior year quarter

Peer trimmed avg / median

Loading

U.S. Stem Cell Long Term Debt History

Loading

U.S. Stem Cell vs. peers: Long Term Debt Comparison

Loading

U.S. Stem Cell Long Term Debt Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

U.S. Stem Cell (USRM) FAQ

As of the most recent data (December 2022), USRM shows a long-term debt of $680K. That compares with $720K in the prior-year period — down 5.5% year over year. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, USRM's long-term debt is now $680K (was $720K) — a 5.5% year-over-year decrease. Pairing that YoY change with peer averages gives a clearer picture of whether U.S. Stem Cell is outperforming or lagging.

Tracking USRM's long-term debt over time shows whether U.S. Stem Cell is scaling, shrinking, or reshaping that part of the business. The current reading is $680K That compares with $720K in the prior-year period — down 5.5% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this long-term debt page, Stockcircle has U.S. Stem Cell's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect long-term debt (currently $680K) with ownership activity and broader fundamentals.

U.S. Stem Cell's long-term debt is $680K; compare it with other Healthcare names on the peer chart. Typical ranges vary by sub-industry, so always sanity-check against the closest competitors, not just the whole sector bucket.